TY - JOUR
T1 - NCCN Guidelines® Insights
T2 - Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024
AU - Daly, Mary B.
AU - Pal, Tuya
AU - Maxwell, Kara N.
AU - Churpek, Jane
AU - Kohlmann, Wendy
AU - AlHilli, Zahraa
AU - Arun, Banu
AU - Buys, Saundra S.
AU - Cheng, Heather
AU - Domchek, Susan M.
AU - Friedman, Susan
AU - Giri, Veda
AU - Goggins, Michael
AU - Hagemann, Andrea
AU - Hendrix, Ashley
AU - Hutton, Mollie L.
AU - Karlan, Beth Y.
AU - Kassem, Nawal
AU - Khan, Seema
AU - Khoury, Katia
AU - Kurian, Allison W.
AU - Laronga, Christine
AU - Mak, Julie S.
AU - Mansour, John
AU - McDonnell, Kevin
AU - Menendez, Carolyn S.
AU - Merajver, Sofia D.
AU - Norquist, Barbara S.
AU - Offit, Kenneth
AU - Rash, Dominique
AU - Reiser, Gwen
AU - Senter-Jamieson, Leigha
AU - Shannon, Kristen Mahoney
AU - Visvanathan, Kala
AU - Welborn, Jeanna
AU - Wick, Myra J.
AU - Wood, Marie
AU - Yurgelun, Matthew B.
AU - Dwyer, Mary A.
AU - Darlow, Susan D.
N1 - Publisher Copyright:
© 2023 National Comprehensive Cancer Network® (NCCN®), All rights reserved.
PY - 2023/10
Y1 - 2023/10
N2 - The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic/ likely pathogenic (P/LP) variants associated with increased risk of breast, ovarian, pancreatic, and prostate cancer, including BRCA1, BRCA2, CDH1, PALB2, PTEN, and TP53, and recommended approaches to genetic counseling/testing and care strategies in individuals with these P/LP variants. These NCCN Guidelines Insights summarize important updates regarding: (1) a new section for transgender, nonbinary and gender diverse people who have a hereditary predisposition to cancer focused on risk reduction strategies for ovarian cancer, uterine cancer, prostate cancer, and breast cancer; and (2) testing criteria and management associated with TP53 P/LP variants and Li-Fraumeni syndrome.
AB - The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic/ likely pathogenic (P/LP) variants associated with increased risk of breast, ovarian, pancreatic, and prostate cancer, including BRCA1, BRCA2, CDH1, PALB2, PTEN, and TP53, and recommended approaches to genetic counseling/testing and care strategies in individuals with these P/LP variants. These NCCN Guidelines Insights summarize important updates regarding: (1) a new section for transgender, nonbinary and gender diverse people who have a hereditary predisposition to cancer focused on risk reduction strategies for ovarian cancer, uterine cancer, prostate cancer, and breast cancer; and (2) testing criteria and management associated with TP53 P/LP variants and Li-Fraumeni syndrome.
KW - Breast Neoplasms/diagnosis
KW - Female
KW - Genetic Predisposition to Disease
KW - Genetic Testing
KW - Germ-Line Mutation
KW - Humans
KW - Male
KW - Ovarian Neoplasms/diagnosis
KW - Risk Factors
UR - https://www.scopus.com/pages/publications/85174941116
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:001097901600007&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.6004/jnccn.2023.0051
DO - 10.6004/jnccn.2023.0051
M3 - Article
C2 - 37856201
SN - 1540-1405
VL - 21
SP - 1000
EP - 1010
JO - Journal of the National Comprehensive Cancer Network : JNCCN
JF - Journal of the National Comprehensive Cancer Network : JNCCN
IS - 10
ER -